Imunon, INC. (IMNN) — 10-K Filings
All 10-K filings from Imunon, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Imunon's Ovarian Cancer Drug Advances to Phase 3, Showing Strong Early Efficacy
— Mar 31, 2026 Risk: high
Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing non-viral DNA technology for innovative treatments. The company's lead progr - 10-K Filing — Feb 27, 2025
-
Imunon, Inc. Files 2023 Annual Report on Form 10-K
— Mar 28, 2024 Risk: medium
Imunon, Inc. (IMNN) filed a Annual Report (10-K) with the SEC on March 28, 2024. Imunon, Inc. filed its 10-K for the fiscal year ending December 31, 2023. The c
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX